📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
23 announcements match the current filters (relevance ≥ 5).
Amanta Healthcare Q3 PAT Up 8% YoY; 9MFY26 PAT Surges 51% to ₹9.3 Cr
Amanta Healthcare reported a steady performance for Q3FY26 with revenue growing 9.84% YoY to ₹74.49 crore. The nine-month (9MFY26) performance was particularly strong in terms of profitability, with PAT surging 51.28% YoY to ₹9.3 crore. EBITDA margins for the 9-month period improved by 42 bps to 21.31%, although quarterly margins saw a slight compression of 159 bps. The company is currently executing a capacity expansion for high-margin SteriPort and SVP products, which is expected to drive growth from Q4 onwards.
Key Highlights
9MFY26 PAT increased by 51.28% YoY to ₹9.3 crore, driven by operational efficiency.
Q3FY26 Revenue grew 9.84% YoY to ₹74.49 crore, reflecting volume-led demand.
9MFY26 EBITDA margins expanded by 42 bps to 21.31% despite quarterly fluctuations.
The company is scaling high-margin SteriPort and SVP capacities to accelerate growth.
Green energy initiatives are being implemented for structural cost optimization.
👀 What to Watch
Investors should monitor the commissioning of the new capacities in Q4, as management expects accelerated growth. The significant jump in 9-month profitability suggests improving operational leverage.
Amanta Healthcare Approves Q3 FY26 Unaudited Financial Results
Amanta Healthcare Limited's Board of Directors approved the standalone unaudited financial results for the quarter and nine months ended December 31, 2025. The statutory auditors, Price Waterhouse Chartered Accountants LLP, provided a Limited Review Report with an unmodified opinion, suggesting no material discrepancies in the reporting. The meeting was held on February 10, 2026, ensuring timely regulatory compliance with SEBI listing obligations. Investors should note that the audit opinion confirms the financial statements are prepared in accordance with Indian Accounting Standards.
Key Highlights
Board approved standalone unaudited financial results for the quarter and nine months ended December 31, 2025
Statutory auditor Price Waterhouse Chartered Accountants LLP issued a Limited Review Report with an unmodified opinion
The board meeting was conducted on February 10, 2026, between 12:00 PM and 01:00 PM
Compliance maintained under Regulation 30 and 33 of SEBI (LODR) Regulations, 2015
👀 What to Watch
Investors should review the detailed profit and loss statements to assess the company's margin performance and revenue growth. The clean auditor's report provides a level of assurance regarding the integrity of the financial disclosures.
Amanta Healthcare Corrects Solar Plant Capacity to 10.8 MWp for Captive Consumption
Amanta Healthcare Limited has clarified a significant clerical error regarding its solar power project, correcting the capacity from 10.8 KWp to 10.8 MWp. The company has re-executed its agreement with Zodiac Energy Limited to reflect this 1,000x increase in planned capacity. The 10.8 MWp plant will be located in Kheda, Gujarat, and is dedicated to captive consumption. This move is expected to substantially reduce the company's long-term energy costs and improve its ESG profile.
Key Highlights
Corrected solar power plant capacity from 10.8 KWp to 10.8 MWp
Agreement re-executed with Zodiac Energy Limited on January 02, 2026
Project located at Village Baroda, District Kheda, Gujarat
Plant intended for captive consumption to reduce operational electricity expenses
No other terms or conditions of the original agreement have been changed
👀 What to Watch
Investors should view this correction positively as a 10.8 MWp plant represents a significant infrastructure investment compared to the previously stated minor installation. Monitor for future updates regarding the commissioning date and the resulting impact on operating margins.
